US Patent Issued to LENTIGEN TECHNOLOGY on Nov. 11 for "Chimeric antigen receptor therapies for treating solid tumors" (Maryland, Utah Inventors)

ALEXANDRIA, Va., Nov. 11 -- United States Patent no. 12,465,641, issued on Nov. 11, was assigned to LENTIGEN TECHNOLOGY INC. (Gaithersburg, Md.).

"Chimeric antigen receptor therapies for treating solid tumors" was invented by Dina Schneider (Potomac, Md.), Peirong Hu (Ijamsville, Md.), Tri Minh Tran (Frederick, Md.), Brittany Steimle (Gaithersburg, Md.) and Aldo Sotelo (Sandy, Utah).

According to the abstract* released by the U.S. Patent & Trademark Office: "Novel anti-effector moiety antibodies or antigen binding domains thereof and CARs that contain such effector moiety antigen binding domains, either with or without one or more booster elements, and host cells expressing the receptors, and nucleic acid molecules encoding the receptors ...